Drug intelligence / Profile preview

OTX-BDI

Development stage: Preclinical
Lead developer: Ocular Therapeutix
Administration: Ophthalmic

Overview

OTX-BDI is an investigational ophthalmic product candidate from Ocular Therapeutix intended for **post-operative dry eye**. Publicly available company disclosures identify it only at a high level as part of the company's hydrogel-based ocular drug delivery pipeline, but do **not** clearly disclose the active ingredient, exact formulation, route-specific product configuration, or molecular mechanism of action. Based on the available evidence, OTX-BDI appears to have remained an early preclinical program and has not been prominently advanced in later pipeline disclosures.

Beyond the preview

Go deeper on OTX-BDI.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OTX-BDI.

Explore the full profile